Anna N. Arefeva
Research Subjects
Anna N. Arefeva has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Sergey M. Noskov
Yaroslavl State Medical University
5 shared publications - Veniamin Valerevich Banko
CJSC “Pharm Holding
5 shared publications - Igor E. Makarenko
Russian University of Medicine. 2. Pharm-Holding
4 shared publications - Igor E. Shokhin
Limited Liability Company "Center of Pharmaceutical Analytics" (LLC "CPHA"); National Research Nuclear University MEPhI (Moscow Engineering Physics Institute)
3 shared publications - O. A. Archakova
Limited Liability Company "Center of Pharmaceutical Analytics" (LLC "CPHA")
3 shared publications - Roman V. Drai
Closed Joint-Stock Company "Pharm-Holding
3 shared publications
Latest Publications
- 9 December 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (3) , 1791-1799
Immunogenicity, efficacy and safety of a biosimilar insulin glulisine compared with originator in adults with type 1 diabetes mellitus: A phase III randomised clinical trial
Aims: To evaluate the immunogenicity, efficacy, and safety of a biosimilar insulin glulisine candidate (T‐Glu) compared to the reference product (R‐Glu) in patients with type 1 diabetes mellitus (T1DM). Materials and Methods: In this phase III, randomised, open‐label trial, adult patients with T1DM received either T‐Glu or R‐Glu by prefilled pens as their bolus insulin for 26 weeks. The primary outcome was the proportion of patients with an immune response at Week 26. Secondary endpoints included changes in glycaemia control parameters, insulin dose stability, treatment satisfaction, and other immunogenicity and safety outcomes. Results: By Week 26, the immune response persisted in 16% of patients in the T‐Glu group and 24% in the R‐Glu group ( p > 0.05), confirming similar immunogenicity. HbA1c reduction at Week 26 compared to baseline was similar between groups, with a mean change of 0.53% ± 1.19% in the T‐Glu group and 0.38% ± 1.46% in the R‐Glu group (mean difference: −0.15%, 95% CI: −0.50 to 0.20), demonstrating non‐inferiority (according to a predefined margin of 0.4%). Fasting plasma glucose levels and the seven‐point glucose profile showed no significant differences between groups ( p > 0.05). Insulin dose remained stable throughout the study, and treatment satisfaction scores improved comparably in both groups ( p > 0.05). The total number of AEs was similar, and hypoglycaemia was more frequent in the R‐Glu group ( p < 0.001), with no new safety concerns identified. Conclusions: T‐Glu demonstrated similar immunogenicity, efficacy, and safety to R‐Glu in adults with T1DM, supporting its use as a biosimilar insulin glulisine. ClinicalTrials.gov : NCT07070752.
- 9 December 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (3) , 1791-1799
Immunogenicity, efficacy and safety of a biosimilar insulin glulisine compared with originator in adults with type 1 diabetes mellitus: A phase III randomised clinical trial
Aims: To evaluate the immunogenicity, efficacy, and safety of a biosimilar insulin glulisine candidate (T‐Glu) compared to the reference product (R‐Glu) in patients with type 1 diabetes mellitus (T1DM). Materials and Methods: In this phase III, randomised, open‐label trial, adult patients with T1DM received either T‐Glu or R‐Glu by prefilled pens as their bolus insulin for 26 weeks. The primary outcome was the proportion of patients with an immune response at Week 26. Secondary endpoints included changes in glycaemia control parameters, insulin dose stability, treatment satisfaction, and other immunogenicity and safety outcomes. Results: By Week 26, the immune response persisted in 16% of patients in the T‐Glu group and 24% in the R‐Glu group ( p > 0.05), confirming similar immunogenicity. HbA1c reduction at Week 26 compared to baseline was similar between groups, with a mean change of 0.53% ± 1.19% in the T‐Glu group and 0.38% ± 1.46% in the R‐Glu group (mean difference: −0.15%, 95% CI: −0.50 to 0.20), demonstrating non‐inferiority (according to a predefined margin of 0.4%). Fasting plasma glucose levels and the seven‐point glucose profile showed no significant differences between groups ( p > 0.05). Insulin dose remained stable throughout the study, and treatment satisfaction scores improved comparably in both groups ( p > 0.05). The total number of AEs was similar, and hypoglycaemia was more frequent in the R‐Glu group ( p < 0.001), with no new safety concerns identified. Conclusions: T‐Glu demonstrated similar immunogenicity, efficacy, and safety to R‐Glu in adults with T1DM, supporting its use as a biosimilar insulin glulisine. ClinicalTrials.gov : NCT07070752.
- Open Access
- 1 November 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 246-255
Application of liquid chromatography-mass spectrometry for the determination of semaglutide in human serum in clinical pharmacokinetic studies
Introduction. Semaglutide preparations are an important therapeutic option for patients suffering from type 2 diabetes mellitus and obesity due to their high efficacy and the expected increase in the prevalence of these diseases. Consequently, there is a growing need for the development of domestic analogs of semaglutide requiring bioequivalence studies. This study proposes the use of high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS) as an alternative to the widely used immunoassay for the quantitative determination of semaglutide in human serum.Aim. To develop and validate a method for the quantitative determination of semaglutide in human serum using HPLC-MS/MS.Materials and methods. Serum sample preparation was based on protein precipitation using an acetonitrile-methanol mixture. Liraglutide was selected as the internal standard. The mobile phase consisted of 0.3% formic acid in water and acetonitrile. The stationary phase was represented by a Phenomenex Kinetex C18 chromatographic column 100×3.0 mm, 5 μm, 100 Å. Ionization of semaglutide and liraglutide was performed in positive electrospray mode. Detection was carried out in multiple reaction monitoring mode (MRM).Results. The method demonstrated high accuracy and precision, with relative error and relative standard deviation values of less than 15% across all quality control levels. The confirmed analytical ranges of the method were 0.50–200.00 ng/mL and 1.00–800.00 ng/mL. Over 3.400 volunteer samples were analyzed as part of the studies. Compared to the ELISA method, the proposed method provides higher selectivity and reproducibility of measurements.Conclusions. The method has been developed that provides reproducible quantitative determination of semaglutide in human blood serum. The method was validated in accordance with EAEU requirements and was successfully applied in bioequivalence studies of semaglutide GP40331 (GEROPHARM LLC, Russia). The method is suitable for conducting pharmacokinetic studies of other semaglutide preparations.
- 1 November 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 246-255
Open AccessApplication of liquid chromatography-mass spectrometry for the determination of semaglutide in human serum in clinical pharmacokinetic studies
Introduction. Semaglutide preparations are an important therapeutic option for patients suffering from type 2 diabetes mellitus and obesity due to their high efficacy and the expected increase in the prevalence of these diseases. Consequently, there is a growing need for the development of domestic analogs of semaglutide requiring bioequivalence studies. This study proposes the use of high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS) as an alternative to the widely used immunoassay for the quantitative determination of semaglutide in human serum.Aim. To develop and validate a method for the quantitative determination of semaglutide in human serum using HPLC-MS/MS.Materials and methods. Serum sample preparation was based on protein precipitation using an acetonitrile-methanol mixture. Liraglutide was selected as the internal standard. The mobile phase consisted of 0.3% formic acid in water and acetonitrile. The stationary phase was represented by a Phenomenex Kinetex C18 chromatographic column 100×3.0 mm, 5 μm, 100 Å. Ionization of semaglutide and liraglutide was performed in positive electrospray mode. Detection was carried out in multiple reaction monitoring mode (MRM).Results. The method demonstrated high accuracy and precision, with relative error and relative standard deviation values of less than 15% across all quality control levels. The confirmed analytical ranges of the method were 0.50–200.00 ng/mL and 1.00–800.00 ng/mL. Over 3.400 volunteer samples were analyzed as part of the studies. Compared to the ELISA method, the proposed method provides higher selectivity and reproducibility of measurements.Conclusions. The method has been developed that provides reproducible quantitative determination of semaglutide in human blood serum. The method was validated in accordance with EAEU requirements and was successfully applied in bioequivalence studies of semaglutide GP40331 (GEROPHARM LLC, Russia). The method is suitable for conducting pharmacokinetic studies of other semaglutide preparations.
- Open Access
- 1 November 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 216-222
Semaglutide for the treatment of obesity: Results of two open randomized pharmacokinetic studies
Introduction. Obesity is a growing public health issue in Russia, increasing the risk of cardiovascular diseases, type 2 diabetes, and hypertension. Controlling obesity involves lifestyle changes and pharmacotherapy. Semaglutide, an effective obesity treatment, stimulates insulin production and reduces appetite. Developing a generic semaglutide preparation will improve its availability in Russia.Aim. To study the comparative pharmacokinetics, bioequivalence, safety and tolerability of semaglutide products GP40331 and Wegovy using concentrations of 0.68 and 3.2 mg/ml in healthy volunteers under fasting conditions.Materials and methods. Bioequivalence studies, conducted per Good Clinical Practice, were open-label, randomized, and involved healthy male volunteers. Subjects received semaglutide at single doses of 0.25 mg (0.68 mg/ml) and 0.5 mg (3.2 mg/ml) under fasting. Bioequivalence was determined by the 90% CI of the ratios of geometric mean values of the primary pharmacokinetic parameters (AUC0-t, Cmax). Semaglutide concentrations were measured using high-performance liquid chromatography with tandem mass spectrometry.Results. The 90% CI values for the ratios of geometric means of the primary PK parameters of semaglutide were 90.22–110.29 and 86.48–108.98% (0.68 mg/ml) and 90.62–115.71 and 92.86–113.51% (3.2 mg/ml). Comparable safety was proven for both concentrations.Conclusion. GP40331 and Wegovy at 0.68 and 3.2 mg/mL are bioequivalent and equally safe.
- 1 November 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 216-222
Open AccessSemaglutide for the treatment of obesity: Results of two open randomized pharmacokinetic studies
Introduction. Obesity is a growing public health issue in Russia, increasing the risk of cardiovascular diseases, type 2 diabetes, and hypertension. Controlling obesity involves lifestyle changes and pharmacotherapy. Semaglutide, an effective obesity treatment, stimulates insulin production and reduces appetite. Developing a generic semaglutide preparation will improve its availability in Russia.Aim. To study the comparative pharmacokinetics, bioequivalence, safety and tolerability of semaglutide products GP40331 and Wegovy using concentrations of 0.68 and 3.2 mg/ml in healthy volunteers under fasting conditions.Materials and methods. Bioequivalence studies, conducted per Good Clinical Practice, were open-label, randomized, and involved healthy male volunteers. Subjects received semaglutide at single doses of 0.25 mg (0.68 mg/ml) and 0.5 mg (3.2 mg/ml) under fasting. Bioequivalence was determined by the 90% CI of the ratios of geometric mean values of the primary pharmacokinetic parameters (AUC0-t, Cmax). Semaglutide concentrations were measured using high-performance liquid chromatography with tandem mass spectrometry.Results. The 90% CI values for the ratios of geometric means of the primary PK parameters of semaglutide were 90.22–110.29 and 86.48–108.98% (0.68 mg/ml) and 90.62–115.71 and 92.86–113.51% (3.2 mg/ml). Comparable safety was proven for both concentrations.Conclusion. GP40331 and Wegovy at 0.68 and 3.2 mg/mL are bioequivalent and equally safe.
- Open Access
- 3 September 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 13,p. 174-180
The first biosimilar of ultra-rapid insulin lispro: results of a double-blind randomised clamp study
Introduction. Over the years, insulin therapy has remained an important component of the complex treatment of patients with diabetes mellitus. Ultra-rapid insulin lispro is a DNA recombinant analogue of human insulin, which has a pharmacokinetic (PK) profile that is as close as possible to the endogenous insulin secretion profile, which ensures effective control of postprandial glycaemia. The development of the ultra-rapid insulin lispro biosimilar will expand the range and increase the availability of modern and safe insulin analogues for diabetic patients in Russia.Aim. To compare the PK and pharmacodynamic (PD) profiles of GP40261 (ultra-rapid insulin lispro biosimilar) and the reference Lyumjev® in healthy volunteers.Materials and methods. This was a double-blind, randomised, comparative, crossover study in healthy volunteers who were administered either the test or reference ultra-rapid insulin lispro formulation as a single dose of 0.3 IU/kg. The hyperinsulinaemic euglycaemic clamp technique was used to evaluate the pharmacokinetics and pharmacodynamics of the study products. In order to assess the biosimilarity of the products, 90% confidence intervals (CIs) were calculated for geometric mean ratios of the primary PK parameters AUCins.0-t and Cins.max. The PD parameters of the study drugs were evaluated based on the glucose infusion rate required to maintain the target glycaemic level during the clamp.Results. The 90% CIs for the geometric mean ratios of the primary PK parameters for the test and reference products were 89.41-94.55% for AUCins.0-t and 82.74-92.92% for Cins.max, which complies with the established acceptance limits of 80-125% for both parameters. The study products were also found to have comparable PD profiles of their active substances.Conclusion. This clinical study has demonstrated that GP40261 and the reference ultra-rapid insulin lispro are biosimilar and have a comparable safety profile.
- 3 September 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 13,p. 174-180
Open AccessThe first biosimilar of ultra-rapid insulin lispro: results of a double-blind randomised clamp study
Introduction. Over the years, insulin therapy has remained an important component of the complex treatment of patients with diabetes mellitus. Ultra-rapid insulin lispro is a DNA recombinant analogue of human insulin, which has a pharmacokinetic (PK) profile that is as close as possible to the endogenous insulin secretion profile, which ensures effective control of postprandial glycaemia. The development of the ultra-rapid insulin lispro biosimilar will expand the range and increase the availability of modern and safe insulin analogues for diabetic patients in Russia.Aim. To compare the PK and pharmacodynamic (PD) profiles of GP40261 (ultra-rapid insulin lispro biosimilar) and the reference Lyumjev® in healthy volunteers.Materials and methods. This was a double-blind, randomised, comparative, crossover study in healthy volunteers who were administered either the test or reference ultra-rapid insulin lispro formulation as a single dose of 0.3 IU/kg. The hyperinsulinaemic euglycaemic clamp technique was used to evaluate the pharmacokinetics and pharmacodynamics of the study products. In order to assess the biosimilarity of the products, 90% confidence intervals (CIs) were calculated for geometric mean ratios of the primary PK parameters AUCins.0-t and Cins.max. The PD parameters of the study drugs were evaluated based on the glucose infusion rate required to maintain the target glycaemic level during the clamp.Results. The 90% CIs for the geometric mean ratios of the primary PK parameters for the test and reference products were 89.41-94.55% for AUCins.0-t and 82.74-92.92% for Cins.max, which complies with the established acceptance limits of 80-125% for both parameters. The study products were also found to have comparable PD profiles of their active substances.Conclusion. This clinical study has demonstrated that GP40261 and the reference ultra-rapid insulin lispro are biosimilar and have a comparable safety profile.
- Open Access
- 26 February 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 1,p. 135-142
Results of biosimilar assessing of insulin aspart preparations of Russian and foreign production using the hyperinsulinemic euglycemic clamp method and studying the use of a new ultra-fast-acting Russian biosimilar in pumps
Introduction. Ultra-fast-acting insulin aspart has great potential for improving postprandial glycemia in patients with type 1 and type 2 diabetes mellitus due to its pharmacological characteristics. The development and production of biosimilars are increasing the availability of modern insulins for patients.Aim. To evaluate the comparability of the pharmacokinetics and pharmacodynamics profiles of insulin aspart GP40311 (tested biosimilar of domestic production) and the reference drug (produced in Denmark) under conditions of a hyperinsulinemic euglycemic clamp in healthy volunteers. To evaluate the stability of a new ultrafast-acting biosimilar when used for continuous subcutaneous infusion in insulin pumps.Materials and methods. Double-blind, randomized, crossover study assessing the pharmacokinetics, pharmacodynamics and safety of the tested biosimilar GP40311 of domestic production and the reference drug produced in Denmark, in the form of a solution for intravenous and subcutaneous administration of 100 IU/ml, the study was conducted under conditions of a hyperinsulinemic euglycemic clamp with the participation of 36 healthy volunteers. A study of the stability, dosing accuracy and tendency to catheter occlusion of a domestic drug for continuous subcutaneous infusion was carried out using several types of insulin pumps using the gravimetric method for 72 hours. Dosing accuracy was determined at the minimum and maximum bolus dose, stability was assessed by pH and quantitative insulin content aspart. The quantitative content of insulin and impurities was assessed by high-performance liquid chromatography.Results and discission. The 90% confidence interval for the ratio of geometric mean values of the main parameters of pharmacokinetics (AUCins.0-t and Cins.max) of insulin aspart test and reference drugs corresponded to the acceptable values of 80.00– 125.00%, which indicated their biosimilarity. When assessing PD, the comparability of action parameters is shown. The safety of the study drugs is comparable. Domestic insulin aspart met the specification standards when used for continuous subcutaneous infusion according to physicochemical parameters: pH, quantitative determination of insulin aspart, impurity content. The accuracy of dosing and the absence of occlusions in systems for 72 hours when using the drug in pumps have been established.Conclusion. The study drugs were found to be biosimilar and equally safe. Domestic insulin aspart meets specification standards and can be used in various types of pumps.
- 26 February 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 1,p. 135-142
Open AccessResults of biosimilar assessing of insulin aspart preparations of Russian and foreign production using the hyperinsulinemic euglycemic clamp method and studying the use of a new ultra-fast-acting Russian biosimilar in pumps
Introduction. Ultra-fast-acting insulin aspart has great potential for improving postprandial glycemia in patients with type 1 and type 2 diabetes mellitus due to its pharmacological characteristics. The development and production of biosimilars are increasing the availability of modern insulins for patients.Aim. To evaluate the comparability of the pharmacokinetics and pharmacodynamics profiles of insulin aspart GP40311 (tested biosimilar of domestic production) and the reference drug (produced in Denmark) under conditions of a hyperinsulinemic euglycemic clamp in healthy volunteers. To evaluate the stability of a new ultrafast-acting biosimilar when used for continuous subcutaneous infusion in insulin pumps.Materials and methods. Double-blind, randomized, crossover study assessing the pharmacokinetics, pharmacodynamics and safety of the tested biosimilar GP40311 of domestic production and the reference drug produced in Denmark, in the form of a solution for intravenous and subcutaneous administration of 100 IU/ml, the study was conducted under conditions of a hyperinsulinemic euglycemic clamp with the participation of 36 healthy volunteers. A study of the stability, dosing accuracy and tendency to catheter occlusion of a domestic drug for continuous subcutaneous infusion was carried out using several types of insulin pumps using the gravimetric method for 72 hours. Dosing accuracy was determined at the minimum and maximum bolus dose, stability was assessed by pH and quantitative insulin content aspart. The quantitative content of insulin and impurities was assessed by high-performance liquid chromatography.Results and discission. The 90% confidence interval for the ratio of geometric mean values of the main parameters of pharmacokinetics (AUCins.0-t and Cins.max) of insulin aspart test and reference drugs corresponded to the acceptable values of 80.00– 125.00%, which indicated their biosimilarity. When assessing PD, the comparability of action parameters is shown. The safety of the study drugs is comparable. Domestic insulin aspart met the specification standards when used for continuous subcutaneous infusion according to physicochemical parameters: pH, quantitative determination of insulin aspart, impurity content. The accuracy of dosing and the absence of occlusions in systems for 72 hours when using the drug in pumps have been established.Conclusion. The study drugs were found to be biosimilar and equally safe. Domestic insulin aspart meets specification standards and can be used in various types of pumps.
- Open Access
- 21 October 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 77-82
Pharmacokinetics of first semaglutid drug in Russian Federation: results of open-label randomized clinical trial
Introduction. Diabetes mellitus is a chronic disease that can impact all aspects of metabolism. Incretin mimetics, such as semaglutide, are a promising group of drugs to treat type 2 diabetes mellitus both through the improvement of glycemic control and additional effects on the cardiovascular system and body weight. The development of a generic semaglutide-containing drug is a burning issue which settlement will increase the availability of semaglutide in the Russian FederationAim. To study the comparative pharmacokinetics, bioequivalence, safety and tolerability of a semaglutide containing GP40221 and Ozempic® in healthy volunteers.Materials and methods. This open-label, randomized, single-dose, parallel group study assessed the bioequivalence of a single dose of 0.5 mg of the study drugs in healthy male subjects under fasting conditions. The conclusion about the bioequivalence of the brand name drug versus the generic drug was made using the classical approach based on the assessment of 90% confidence intervals of the ratios of geometric means of the primary pharmacokinetic parameters (AUC0-t, Сmax) for the active substance of the study drugs.Results. The results of the study showed that the 90% CI values of the ratios of geometric means of the primary PK parameters of semaglutide were 85.96–109.01% and 89.14–111.40% for AUC0-t и Cmax, respectively, and are well within acceptable limits 80.00–125.00%. The comparable safety of the study drugs containing semaglutide has been proven.Conclusion. Thus, GP40221 (GEROPHARM LLC, Russia) and Ozempic® (Novo Nordisk A/S, Denmark) can be considered bioequivalent and equally safe based on the results of this clinical study. The results of this study allow us to recommend a drug developer to submit specific data on their study drug GP40221 to the Ministry of Health of the Russian Federation to obtain marketing authorization.
- 21 October 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 77-82
Open AccessPharmacokinetics of first semaglutid drug in Russian Federation: results of open-label randomized clinical trial
Introduction. Diabetes mellitus is a chronic disease that can impact all aspects of metabolism. Incretin mimetics, such as semaglutide, are a promising group of drugs to treat type 2 diabetes mellitus both through the improvement of glycemic control and additional effects on the cardiovascular system and body weight. The development of a generic semaglutide-containing drug is a burning issue which settlement will increase the availability of semaglutide in the Russian FederationAim. To study the comparative pharmacokinetics, bioequivalence, safety and tolerability of a semaglutide containing GP40221 and Ozempic® in healthy volunteers.Materials and methods. This open-label, randomized, single-dose, parallel group study assessed the bioequivalence of a single dose of 0.5 mg of the study drugs in healthy male subjects under fasting conditions. The conclusion about the bioequivalence of the brand name drug versus the generic drug was made using the classical approach based on the assessment of 90% confidence intervals of the ratios of geometric means of the primary pharmacokinetic parameters (AUC0-t, Сmax) for the active substance of the study drugs.Results. The results of the study showed that the 90% CI values of the ratios of geometric means of the primary PK parameters of semaglutide were 85.96–109.01% and 89.14–111.40% for AUC0-t и Cmax, respectively, and are well within acceptable limits 80.00–125.00%. The comparable safety of the study drugs containing semaglutide has been proven.Conclusion. Thus, GP40221 (GEROPHARM LLC, Russia) and Ozempic® (Novo Nordisk A/S, Denmark) can be considered bioequivalent and equally safe based on the results of this clinical study. The results of this study allow us to recommend a drug developer to submit specific data on their study drug GP40221 to the Ministry of Health of the Russian Federation to obtain marketing authorization.
- Open Access
- 1 September 2023
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 12 (3) , 218-227
An Open-label Randomized Crossover Study with Adaptive Design of the Pharmacokinetics and Bioequivalence of GP30121 and Ceraxon® Corrected for Endogenous Analyte Level
Introduction. Citicoline is an endogenous nucleoside consisting of cytidine and choline linked by a diphosphate bridge that is involved in the synthesis of membrane phospholipids. Drugs containing citicoline have neuroprotective and neurometabolic effects and are used for the treatment of a wide range of neurological disorders. In its turn, bioequivalence study is a pathway to register a generic citicoline drug in Russian Federation.Aim. The aim of the study was to investigate the comparative pharmacokinetics (PK) and bioequivalence of two citicoline-containing drugs GP30121 and Ceraxon® in healthy male volunteers when taken on an empty stomach.Materials and methods. We evaluated the pharmacokinetics of citicoline-containing drugs corrected for endogenous analyte (uridine) level using an adaptive design. We determined uridine concentration by high-performance liquid chromatography with mass spectrometric detection. We used R Project software, version 3.6.3. for performing statistical analysis for the study.Results and discussion. GP30121 and Ceraxon® exhibited similar PK profiles. It was shown that the values of 94.12 % confidence interval (CI) at α = 0.0294 for the geometric mean ratios for the primary PK parameters of the main metabolite of the active ingredient of the investigated drugs were fully contained within the predefined equivalence limits of 80.00–125.00 %.Conclusion. The study demonstrates bioequivalence of GP30121 and Ceraxon® proving the approach with the correction for endogenous analyte could be considered in studies of other drugs.
- 1 September 2023
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 12 (3) , 218-227
Open AccessAn Open-label Randomized Crossover Study with Adaptive Design of the Pharmacokinetics and Bioequivalence of GP30121 and Ceraxon® Corrected for Endogenous Analyte Level
Introduction. Citicoline is an endogenous nucleoside consisting of cytidine and choline linked by a diphosphate bridge that is involved in the synthesis of membrane phospholipids. Drugs containing citicoline have neuroprotective and neurometabolic effects and are used for the treatment of a wide range of neurological disorders. In its turn, bioequivalence study is a pathway to register a generic citicoline drug in Russian Federation.Aim. The aim of the study was to investigate the comparative pharmacokinetics (PK) and bioequivalence of two citicoline-containing drugs GP30121 and Ceraxon® in healthy male volunteers when taken on an empty stomach.Materials and methods. We evaluated the pharmacokinetics of citicoline-containing drugs corrected for endogenous analyte (uridine) level using an adaptive design. We determined uridine concentration by high-performance liquid chromatography with mass spectrometric detection. We used R Project software, version 3.6.3. for performing statistical analysis for the study.Results and discussion. GP30121 and Ceraxon® exhibited similar PK profiles. It was shown that the values of 94.12 % confidence interval (CI) at α = 0.0294 for the geometric mean ratios for the primary PK parameters of the main metabolite of the active ingredient of the investigated drugs were fully contained within the predefined equivalence limits of 80.00–125.00 %.Conclusion. The study demonstrates bioequivalence of GP30121 and Ceraxon® proving the approach with the correction for endogenous analyte could be considered in studies of other drugs.
- Open Access
- 10 May 2023
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 4 (1) , 84-88
Klinefelter syndrome: a case report
Klinefelter syndrome (KS) is a genetic disease associated with the presence of an extra X-chromosome in the karyotype of men. The most common karyotype is 47XXY, however, other genetic variants are also possible, as well as mosaic forms.The clinical picture is most often represented by bilateral gynecomastia, decreased in the volume testicles and infertility (azoospermia). Laboratory revealed hypergonadotropic hypogonadism. Testosterone replacement therapy is used to ensure virilization and the proper quality of life. Assisted reproductive technologies with preliminary hormonal preparation are used to restore fertility.This article presents a clinical case of KS and considers options for realization of reproductive plans in the case of non-obstructive azoospermia.
- 10 May 2023
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 4 (1) , 84-88
Open AccessKlinefelter syndrome: a case report
Klinefelter syndrome (KS) is a genetic disease associated with the presence of an extra X-chromosome in the karyotype of men. The most common karyotype is 47XXY, however, other genetic variants are also possible, as well as mosaic forms.The clinical picture is most often represented by bilateral gynecomastia, decreased in the volume testicles and infertility (azoospermia). Laboratory revealed hypergonadotropic hypogonadism. Testosterone replacement therapy is used to ensure virilization and the proper quality of life. Assisted reproductive technologies with preliminary hormonal preparation are used to restore fertility.This article presents a clinical case of KS and considers options for realization of reproductive plans in the case of non-obstructive azoospermia.
- 3 March 2023
- Published by Elsevier in Biologicals
- Vol. 81, 101666
Comparability of biosimilar romiplostim with originator: Protein characterization, animal pharmacodynamics and pharmacokinetics
- 3 March 2023
- Published by Elsevier in Biologicals
- Vol. 81, 101666
Comparability of biosimilar romiplostim with originator: Protein characterization, animal pharmacodynamics and pharmacokinetics